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sychiatryArchival Report BPPositron Emission Tomography Studies of the
Glial Cell Marker Translocator Protein in Patients
With Psychosis: A Meta-analysis Using Individual
Participant Data
Pontus Plavén-Sigray, Granville J. Matheson, Karin Collste, Abhishekh H. Ashok,
Jennifer M. Coughlin, Oliver D. Howes, Romina Mizrahi, Martin G. Pomper, Pablo Rusjan,
Mattia Veronese, Yuchuan Wang, and Simon CervenkaISSABSTRACT
BACKGROUND: Accumulating evidence suggests that the immune system may be an important target for new
treatment approaches in schizophrenia. Positron emission tomography and radioligands binding to the translocator
protein (TSPO), which is expressed in glial cells in the brain including immune cells, represents a potential method for
patient stratification and treatment monitoring. This study examined whether patients with first-episode psychosis
and schizophrenia had altered TSPO levels compared with healthy control subjects.
METHODS: PubMed was searched for studies comparing patients with psychosis with healthy control subjects using
second-generation TSPO radioligands. The outcome measure was total distribution volume (VT), an index of TSPO
levels, in frontal cortex, temporal cortex, and hippocampus. Bayes factors (BFs) were applied to examine the
relative support for higher, lower, or no difference in patients’ TSPO levels compared with healthy control subjects.
RESULTS: Five studies, with 75 participants with first-episode psychosis or schizophrenia and 77 healthy
control subjects, were included. BFs showed strong support for lower VT in patients relative to no difference
(all BFs . 32), or relative to higher VT (all BFs . 422), in all brain regions. From the posterior distributions,
mean patient–control differences in standardized VT values were 20.48 for frontal cortex (95% credible
interval [CredInt] = 20.88 to 0.09), 20.47 for temporal cortex (CredInt = 20.87 to 20.07), and 20.63 for
hippocampus (CredInt = 21.00 to 20.25).
CONCLUSIONS: The lower levels of TSPO observed in patients may correspond to altered function or lower density
of brain immune cells. Future studies should focus on investigating the underlying biological mechanisms and their
relevance for treatment.
Keywords: Immune activation, Meta-analysis, Microglia, Positron emission tomography, Psychosis, Schizophrenia,
Translocator protein
https://doi.org/10.1016/j.biopsych.2018.02.1171Genetic, epidemiological, and biomolecular data suggest
that the immune system is involved in the pathophysiology of
schizophrenia (1–3). When translating these findings into
clinical trials, initial studies have shown a positive effect of
medication targeting the immune system when used as an
add-on treatment to antipsychotics (4–6). To aid further
development of this therapeutic approach, tools for directly
assessing the status of the brain immune system are needed
to allow for patient stratification and monitoring of treatment
effects.
Using positron emission tomography (PET), the localization
and activation state of central nervous system immune
response modulators can be assessed with radioligands tar-
geting the 18-kDa translocator protein (TSPO), which isSEE COMMENTARY
ª 2018 Society of Biological Psychiatry. Pu
CC BY-NC-ND
N: 0006-3223 Biologicaexpressed in glial cells (7–9). During the last decade, a handful
of TSPO PET studies have been performed in patients with
early-stage psychosis or manifest schizophrenia, showing
inconclusive results. Early reports using the first-generation
TSPO radioligand (R)-[11C]PK11195 showed higher binding in
small patient groups (n = 7 and n = 10) (10,11), albeit with
outcome measures that show low accuracy and reliability
(i.e., binding potential estimated from rate constants) (12–14).
More recent studies in larger samples using the same radio-
ligand, but without blood sampling for full quantification, did
not replicate these findings (15–17). Concerns regarding the
low signal-to-noise ratio of (R)-[ 11C]PK11195 sparked the
development of a series of second-generation TSPO radio-
ligands, showing much greater specific binding (18–21). TheseON PAGE e43
blished by Elsevier Inc. This is an open access article under the
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Psychiatrytools have subsequently been used to revisit the question of
higher levels of TSPO in psychosis (22–26). When employing
gold standard outcome measures of binding in the absence of
a reference region (total distribution volume [VT] obtained
using kinetic modeling with metabolite-corrected arterial
plasma as input function), higher TSPO expression has so far
not been found in patients. In some cases, trend-level (24) or
significantly lower (23) TSPO levels were shown.
All previous TSPO PET studies in psychosis have been
performed with relatively small sample sizes. In addition,
TSPO radioligands display substantial within- and between-
subject variability (12,27) even after accounting for the TSPO
rs6971 polymorphism that is known to affect radioligand
binding in vivo (28–30). This has important implications for
sensitivity and the power to detect differences between
patients with psychosis and control subjects. Indeed, the
power to detect an expected significant medium-sized dif-
ference between diagnostic groups (at alpha = .05) has
ranged from 23% to 34% in previous designs (22–26).
Medication status has also differed both between and within
these studies. Because antipsychotics have been shown to
dampen the immune response, this further limits the con-
clusions that can be drawn (31). Here, we sought to over-
come these limitations and clarify the use of TSPO PET as a
biomarker of immune dysfunction in schizophrenia. We
conducted an individual participant data (IPD) meta-analysis
of all TSPO PET studies performed in psychosis or schizo-
phrenia using second-generation radioligands, where VT was
included as the outcome measure. The primary objective
was to evaluate the hypotheses of 1) higher, 2) lower, or 3) no
difference in VT between patients and healthy control sub-
jects (HCs). A secondary objective was to assess the effects
of antipsychotic medication on TSPO levels.
METHODS AND MATERIALS
Preferred Reporting Items for Systematic Reviews
and Meta-analyses, Preregistration, and Code
Availability
This meta-analysis was conducted according to the Preferred
Reporting Items for Systematic Reviews and Meta-analyses of
IPD (PRISMA-IPD) (32) and according to a study-specific
preregistration protocol. The preregistration protocol and all
codes used in this study can be found on the public repository
(https://github.com/pontusps/TSPO_psychosis).
Selection Criteria and Search Strategy
We set out to obtain IPD from all PET studies that 1) used a
second-generation TSPO radioligand, 2) reported VT values in
the central nervous system in subjects with psychosis or
schizophrenia as compared with HCs, and 3) reported TSPO
affinity type of all participants. To our knowledge, there are
currently five published studies reporting such data, using the
radioligands [11C]PBR28, [18F]FEPPA, and [11C]DPA713
(22–26). To ascertain that no relevant studies were omitted
from this meta-analysis, we performed a systematic literature
search on PubMed. Only articles published after 2004 were
included in the search, corresponding to the year when the first
report on a second-generation TSPO radioligand was434 Biological Psychiatry September 15, 2018; 84:433–442 www.sobppublished (33). Search terms included (among others) “psy-
chotic disorder,” “schizophrenia,” “positron emission tomog-
raphy,” “translocator protein 18 kDa,” and “peripheral
benzodiazepine receptor” (for the full list of search terms, see
the Supplement). All TSPO PET studies in psychosis or
schizophrenia that were not included are listed in
Supplemental Table S1 along with a detailed explanation of the
selection criteria. Corresponding authors of eligible studies
were contacted via e-mail, and all agreed to contribute.
Requested Data
Requested IPD included VT values from the frontal cortex (FC),
temporal cortex (TC), and hippocampus (HIP) regions of in-
terest (ROIs), patient–control status, TSPO genotype, age,
gender and medication status, Positive and Negative Syn-
drome Scale (PANSS) scores (or equivalent), and duration of
illness. These three ROIs were selected because four of five
included studies had reported VT values from all of them. For
the remaining study [Bloomfield et al. (22)], unpublished IPD VT
values obtained using the conventional two-tissue compart-
ment model from all three ROIs were provided on request,
allowing for consistent pooling. To account for range differ-
ences among different radioligands used across studies, we Z-
scored all ROI VT values within each genotype group of each
study.
Quality Control
The first author (PP-S) examined the integrity of the obtained
IPD datasets. The data were checked for outliers and in-
consistencies with the published data (such as number of
participants, means, ranges, and SDs of VT and age), which
were then resolved following discussion with the authors of the
relevant studies.
Meta-analysis and Statistics
The studies included in this meta-analysis recruited partici-
pants of two different TSPO affinity types (high-affinity binders
and mixed-affinity binders), used different radioligands, and
applied different image analysis procedures. To estimate the
difference in VT between diagnostic groups (DVT) while taking
this hierarchical structure into account, we constructed and
compared four different Bayesian linear mixed-effects (BLME)
models of increasing complexity: In model 1 (M1), standard-
ized ROI VT was specified as the dependent variable, diag-
nostic group as the fixed effect, and genotype and study as
random effects with varying intercepts. Model 2 (M2) was the
same as M1 but with varying slopes of the random effect of
genotype (i.e., allowing for differences in DVT between high-
affinity binders and mixed-affinity binders). Model 3 (M3) was
the same as M1 but with varying slopes of the random effect of
study (i.e., allowing for differences in DVT between studies).
Model 4 (M4) was the same as M1 but with varying slopes for
both random effects (i.e., allowing for differences in DVT be-
tween genotypes and studies). The model with the best fit to
data, as determined by widely applicable information criterion
and leave-one-out cross-validation scores, was selected (34).
Following model selection, we first examined the hypothesis
that patients with psychosis or schizophrenia have higher
levels of TSPO in the brain (hypothesis 1 [H1]). For each ROI,.org/journal
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Psychiatrywe quantified the relative evidence of higher TSPO expression
in patients compared with the null hypothesis of no difference
(H0). This was done using order-restricted Bayes factor (BF)
hypothesis testing (35–37) on DVT. BF quantifies the relative
evidence, or support, for one hypothesis over another as a
ratio of their average likelihoods. A BF . 10 is usually
considered as strong evidence in favor of a hypothesis (and,
consequently, BF , 0.1 translates into strong evidence of the
opposite hypothesis) (35). We calculated BFH1:H0 to quantify
the evidence in favor of higher ROI VT in patients compared
with control subjects relative to no difference. Second, we
examined whether patients had lower levels of VT in the ROI
(H2). Again, this was done by employing an order-restricted BF
test of lower VT in patients (BFH2:H0) over no difference. Finally,
we calculated the support for H2 over H1 (BFH2:H1), signaling
the relative likelihood of lower levels of TSPO in patients
compared with higher levels.
For each ROI, H1 and H2 were specified as half-Gaussian
(normal) distributions centered on zero with a standard
deviation of 0.5. Hence, to perform order-restricted hy-
pothesis testing of patient–control differences, the priors
over ROI DVT were specified as half Gaussians (SD = 0.5)
with a lower bound of zero for H1 and an upper bound of
zero for H2. The Savage–Dickey ratio method was then used
to calculate BFs. The standard deviation was set a priori to
0.5 because this assigns high plausibility to DVT values
ranging from 0 to a medium-sized difference (38,39). A
medium-sized difference, corresponding to a Cohen’s d of
0.5, was considered a reasonable prediction based on the
precision of the outcome measure (27). A medium effect
size (Cohen’s d = 0.5) group difference in VT means that
69% of the patient population would be expected to have a
higher (or lower) VT than the mean of the population of HCs
[Cohen’s U3 (38)].
A robustness check of the effect of different prior widths on
BF was performed by varying the SDs of the half-Gaussian
distributions (SDs = 0.2 and 0.8, corresponding to expected
small and large effect sizes of DVT and Cohen’s U3 = 58% and
79%, respectively) when testing all hypotheses. For the prior
on the SDs of the random effects, half-Cauchy distributions
(with a scale of 0.707) were used. These weakly informative
priors were chosen because the numbers of genotype groups
(n = 2) and studies (n = 5) are small (40).
We also estimated the overall effect size of standardized VT
difference between patients and HCs. This was done using M3
with a nontruncated, weakly regularizing prior (Gaussian with
an SD of 10) over the fixed effect. M3 was selected because it
also allowed us to extract the study-specific effects of ROI DVT
(random slopes) and the corresponding SDs of these effects
(s). Using these, we produced a forest plot of ROI DVT and
examined s as a measure of study heterogeneity, in line with
the PRISMA-IPD guidelines.
For the secondary aim of analyzing medication effects on
VT, we added an additional predictor, denoting medication
status, to the best-fitting BLME model. This predictor quan-
tifies the additional effect of being medicated after controlling
for patient–control status. For each ROI, the prior distribution
over the beta coefficient was a nontruncated Gaussian
centered on zero with an SD of 10. The posterior of this pre-
dictor was then extracted together with its summary statisticsBiological Psychi(mean and 95% credible interval [CredInt]) to examine the ef-
fect of medication.
We also examined the correlation between ROI VT values
and PANSS-Positive scores, PANSS-Negative scores, and
duration of illness using linear effect modeling, allowing the
correlations to vary between studies. All data were Z-trans-
formed within study (and within genotype for VT).
The primary reason for choosing Bayesian statistical infer-
ence is that the BF allows for a direct comparison of the evi-
dence for one hypothesis relative to another hypothesis (such
as H1 against H2, i.e., higher TSPO in patients vs. lower TSPO
in patients). Bayesian parameter estimation also allowed us to
assess and report the uncertainty around parameters in the
model, which guards against overconfidence and overfitting
when making inference. For completeness, we also present
frequentist equivalents of the best-fitting model, showing p
values for patient–control differences in standardized VT for
each ROI in Supplemental Table S2. The Hamiltonian Markov
chain Monte Carlo sampler Stan (41) and the R packages brms
(42) and lme4 (43) were used for the statistical modeling in this
meta-analysis.
RESULTS
Study Selection and Data Collection
The PubMed search was performed on February 20, 2017, and
resulted in 13 research articles. The articles were read in full by
two of the authors (PP-S and SC). Both authors concluded
independently that five studies (22–26) fulfilled the inclusion
criteria for this meta-analysis (see PRISMA flowchart in
Supplemental Figure S3). Each corresponding author provided
anonymized individual participant VT values from FC [three
studies (22–24)], dorsolateral prefrontal cortex [two studies
(25,26)], TC (all studies), and HIP (all studies). For all subse-
quent analyses in this study, the VT values from FC and
dorsolateral prefrontal cortex were considered to represent the
same ROI.
Characteristics of Included Studies
Table 1 shows demographic information, medication status,
PANSS (or equivalent), and duration of illness of all participants
included in this meta-analysis. In total, IPD from 75 participants
with psychosis or schizophrenia and 77 HCs were included in
the statistical analysis. All patients who participated in Kenk
et al. (26) and Bloomfield et al. (22), and all patients except 2
who participated in Coughlin et al. (24), were on antipsychotic
treatment at the time of PET. Of the 19 patients who partici-
pated in Hafizi et al. (25), 5 were antipsychotic free with less
than 4 weeks of lifetime cumulative exposure and 14 were
antipsychotic naive at the time of scanning. All patients in
Collste et al. (23) were antipsychotic naive. For all studies,
exclusion criteria included clinically significant medical co-
morbidity and substance abuse. In two of the studies benzo-
diazepines were not allowed (22,24), whereas in Collste et al.
(23) and Kenk et al. (26) the results did not change when
removing subjects using benzodiazepines. Based on this in-
formation, as well as in vitro data showing effects of only high
doses of diazepam on TSPO levels (44), we chose not to
include this variable in our analysis. For information onatry September 15, 2018; 84:433–442 www.sobp.org/journal 435
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Psychiatry436 Biological Psychiatry September 15, 2018; 84:433–442 www.sobprecruitment of HCs, quality control of the data, and assignment
of subjects who overlapped in the original studies, see the
Supplement. Figure 1 displays the individual participant ROI VT
values from the five studies included in this meta-analysis.
The mean age of all subjects in the patient group was 33.88
years (SD = 12.57), and the mean age of all subjects in the HC
group was 35.42 years (SD = 15.12). This corresponds to a
negligible difference in age between diagnostic groups
(Cohen’s d = 0.11). Fisher’s exact test indicated some skew-
ness in gender distribution between the patient and control
groups (p = .0504). To ascertain that any potential differences
in ROI VT values between diagnostic groups in the main
analysis were not driven by gender differences, we included
gender as a covariate and executed an additional set of BLME
models, using the same procedure as outlined in Methods and
Materials. It should be noted that we had no information
regarding the menstrual cycle, which could potentially influ-
ence the results in female participants, although relationships
between TSPO and menstrual cycle hormonal levels have as of
yet to be demonstrated.
Model Selection
M1 showed a slightly better fit, determined by widely appli-
cable information criterion and leave-one-out cross-validation
scores, compared with M2 and M3 (Table 2). Therefore, we
used M1 to obtain order-restricted posterior distributions of
ROI DVT and subsequently quantified evidence in favor of H0,
H1, and H2.
Patient–Control Difference in VT (Primary Aim)
BFH1:H0 values in favor of higher VT in patients (H1) were 0.08
for FC, 0.08 for TC, and 0.06 for HIP. This translates into strong
support for the null hypothesis of no difference (H0) relative to
higher levels of TSPO in patients. BFH2:H0 values in favor of
lower VT in patients (H2) were 32.5 for FC, 34.2 for TC, and
1481.0 for HIP compared with H0. This signifies very strong
evidence for the hypothesis that patients express lower TSPO
levels. As a result, there was extremely strong support for H2
over H1 (BFH2:H1 values: FC = 422.9; TC = 440.6; HIP =
24524.0). Hence, lower VT in patients with psychosis, as
compared to with HCs, is more than 422 times more likely than
higher VT, conditioned on the data and the models (see Table 3
and Supplemental Figure S1 for all computed BFs).
When varying the widths (SDs = 0.2 and 0.8) of the Gaussian
prior distribution on the fixed effect of differences between
patients and control subjects, there was still strong support in
favor of H2 for all ROIs (all BFH2:H0 . 15) (see Supplemental
Table S3). The addition of gender as a covariate did not
change the qualitative inference for any of the ROIs (all BFH2:H0
. 16) (see Supplemental Table S4).
Estimation of Effect Sizes and Study Heterogeneity
For estimation of effect sizes and study heterogeneity, M3,
with an uninformative prior over DVT, was used. Figure 2 dis-
plays forest plots of the estimated patient–control difference
in each study for each ROI. It also shows the posterior distri-
butions of the standardized DVT across all studies together
with summary statistics (mean and credible intervals). The
mean of each ROI’s posterior distribution corresponded to a.org/journal
Figure 1. Individual participant raw data showing translocator protein levels (estimated using total distribution volume [VT]) in participants with first-episode
psychosis or schizophrenia and healthy control subjects, from all five included studies, from frontal cortex (FC), temporal cortex (TC), and hippocampus (HIP).
The black bars denote the group means. For each region, subjects’ VT values have been Z-scored within study, and within genotype, in order to produce the
pooled plots of all high-affinity binders (HABs) and mixed-affinity binders (MABs). For this reason, HABs and MABs have the same mean (set to zero) in the
right-hand panels. Included studies: Bloomfield et al. (22); Collste et al. (23); Coughlin et al. (24); Hafizi et al. (25); Kenk et al. (26).
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Psychiatrymedium-sized (i.e., Cohen’s dz 0.5) difference in VT between
patients and control subjects. When calculating group differ-
ences using raw VT values, subjects with psychosis or
schizophrenia had, on average, 15% lower VT in FC, 14%
lower VT in TC, and 24% lower VT in HIP compared with HCs.
For all ROIs, the SDs of the random slopes of studies (s)
were very small (posterior modes , 0.04; posterior means ,
0.22) and I2 , 15%, signifying low study heterogeneity in DVT
differences (see Supplemental Figure S2).
Effect of Medication (Secondary Aim)
We examined the effect of medication on VT by adding
medication status as an additional predictor to M1. For all
ROIs, the models showed little to no evidence of a medication
effect, allocating as much probability to higher VT as they did to
lower VT. The means of the posterior over the difference in
standardized VT due to medication were 0.009 for FC
(CredInt = 20.384 to 0.401), 20.013 for TC (CredInt = 20.407
to 0.381), and 20.040 for HIP (CredInt = 20.423 to 0.343) (seeBiological PsychiFigure 3). Thus, no support was found for a difference in TSPO
levels between drug-free and medicated patients.
There was little to no evidence for a correlation between
regional VT values and PANSS-Positive scores, PANSS-
Negative scores, or duration of illness (see Supplemental
Figures S5 and S6 and Supplemental Tables S5 and S6).
DISCUSSION
The main finding of this IPD meta-analysis was that patients
with schizophrenia and first-episode psychosis showed lower
levels of the glial cell marker TSPO compared with HCs. Using
BLME modeling, we observed very strong evidence of lower
levels of TSPO, measured using VT, in FC, TC, and HIP, con-
trary to the hypothesis of higher TSPO in patients. As such, this
study constitutes the most conclusive in vivo investigation of
TSPO in psychosis to date.
Antipsychotic medication has been shown to attenuate
blood cytokine levels in patients (31) as well as to inhibit im-
mune cell activity in vitro (45). Although the effect on TSPOatry September 15, 2018; 84:433–442 www.sobp.org/journal 437
Table 3. Bayes Factors (BF) of Hypothesis Testing of the
Difference in Standardized Brain TSPO Binding (Estimated
Using VT) Between Patients and Control Subjects Using
the Best-Fitting Model (M1)
Region H0:H1 H1:H0 H0:H2 H2:H0 H1:H2 H2:H1
FC 13.0 0.08 0.03 32.5 0.002 422.9
TC 12.9 0.08 0.03 34.2 0.002 440.6
HIP 16.6 0.06 0.001 1481.0 , 0.001 24524.0
FC, frontal cortex; H0, null hypothesis; H1, hypothesis 1; H2, hypothesis
2; H0:H1, BF denoting evidence in favor of H0 over H1; H1:H0, BF
denoting evidence in favor of H1 over H0; H0:H2, BF denoting evidence
in favor of H0 over H2; H2:H0, BF denoting evidence in favor of H2 over
H0; H1:H2, BF denoting evidence in favor of H1 over H2; H2:H1, BF
denoting evidence in favor of H2 over H1; HIP, hippocampus; M1,
Model 1; TC, temporal cortex; TSPO, translocator protein; VT, total
distribution volume.
Table 2. Model Fits for Four Different Bayesian Linear
Mixed-Effects Models Examining the Difference in TSPO
Binding (Estimated Using VT) Between Patients With
Psychosis and Healthy Control Subjects
Region Model dLOOC dWAIC Akaike Weighta (%)
Frontal Cortex 0 7.6 7.6 1
1 0 0 38
2 0.8 0.8 26
3 1.1 1.1 22
4 1.9 1.9 14
Temporal Cortex 0 7.1 7.1 1
1 0 0 35
2 0.6 0.6 26
3 0.9 0.9 22
4 1.6 1.6 16
Hippocampus 0 15.3 15.4 , 1
1 0 0 36
2 0.4 0.4 29
3 1.3 1.2 19
4 1.7 1.6 16
A null model (0) without patient–control status as predictor is
included as a baseline comparison. Lower dLOOC and dWAIC values
indicate better model fit.
dLOOC, distance to best-fitting model calculated using leave-one-
out cross-validation; dWAIC, distance to best-fitting model calculated
using widely applicable information criteria; TSPO, translocator
protein; VT, total distribution volume.
aWeights calculated using LOOC scores.
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tions suggest that TSPO levels could be lower in medicated
subjects compared with unmedicated subjects. However, our
secondary analysis of the effect of medication status yieldedFigure 2. Standardized difference in translocator protein levels (estimated usin
control subjects. The posterior distribution for each study-specific difference in V
The black circle denotes the posterior mean, and the thick line denotes the 95% c
denotes the patient–control mean difference in raw data (together with its 95% cr
difference between the dot and the cross displays the model shrinkage toward the
first-episode psychosis have lower levels of translocator protein compared with h
(23); Coughlin et al. (24); Hafizi et al. (25); Kenk et al. (26).
438 Biological Psychiatry September 15, 2018; 84:433–442 www.sobpno evidence for such a difference in radioligand binding be-
tween drug-free and medicated patients. This indicates that
the observed lower levels of TSPO in patients is not an effect of
exposure to antipsychotic treatment.
A wealth of data has demonstrated higher levels of
proinflammatory markers, such as cytokines, in cerebrospi-
nal fluid and plasma in patients across disease stages of
schizophrenia (3,47). In the brain, these signaling molecules
are mainly released by microglia and astrocytes, which have
key roles in the immune response (9). Therefore, increases in
numbers or activity of these cells in schizophrenia have been
hypothesized (48,49). In postmortem studies, higher levels of
brain glial cell markers, such as human leukocyte antigen–
antigen D related and CD11b, have been observed in pa-
tients, although results have been mixed (50–52). With re-
gard to astrocyte markers, there is no evidence of any overallg total distribution volume [VT]) between patients with psychosis and healthy
T (DVT) estimate (random slopes) from the linear mixed model is presented.
redible interval; these are also presented in text next to the plots. The cross
edible interval) without performing linear mixed-effects modeling. Hence, the
mean. The overall DVT estimate suggests that patients with schizophrenia or
ealthy control subjects. Included studies: Bloomfield et al. (22); Collste et al.
.org/journal
Figure 3. Posterior distributions over the differences in standardized
brain translocator protein levels (estimated using total distribution volume
[VT]) between patients and control subjects and the additional effect of
medication status (being medicated with antipsychotics or not at the time of
positron emission tomography). The posterior distributions of medication
effect are centered on zero and suggest that antipsychotic treatment does
not affect brain VT after accounting for differences between patients with
psychosis or schizophrenia and control subjects. DVT, difference in VT.
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the case of TSPO, which is expressed in microglia and as-
trocytes among other cells (8,9,53), autoradiographic studies
have reported both higher (28) and lower (54) binding in
patients as compared with HCs. Important caveats when
interpreting these studies are that the age of patients and
control subjects is generally high and the cause of death in
patients is often suicide (52). A recent translational study
examined TSPO in an infection-mediated animal model of
schizophrenia. Higher levels of proinflammatory cytokines
were found in brain regions that also showed lower TSPO
expression as measured using immunohistochemistry (55),
an observation that paralleled TSPO PET and cerebrospinal
fluid data in patients (24). Importantly, microglia and astro-
cytes have been found to exist in both pro- and anti-
inflammatory states (56,57), which cannot be differentiated
by TSPO. Indeed, very recent in vitro data suggest that M1Biological Psychi(proinflammatory) macrophages and microglia may show
lower TSPO expression in humans (58,59). The above-
discussed literature, together with the results of our study,
challenges the utility of TSPO as an exclusively proin-
flammatory marker in schizophrenia. Lower levels of TSPO
could indicate a compensatory mechanism to a proin-
flammatory signal (55,60) or altered function of glial cells
such as abnormal energy use (61). Because stimulation of
TSPO has been shown to attenuate microglial activation in
response to neuroinflammatory challenges (62–64), lower
TSPO in psychosis could also indicate an inherent weaker
anti-inflammatory response. These hypotheses all need to
be addressed in future studies.
Because there is no brain region devoid of TSPO expression
(65,66), metabolite-corrected arterial plasma measurements of
radioligand concentration are necessary for accurate in vivo
quantification of binding. To overcome variability that may be
associated with the arterial measurements (27,67), relative
measures of binding, such as distribution volume ratios
(DVRs), have been proposed (22). Of the studies included in
this meta-analysis, one study reported a significantly higher
DVR in patients with schizophrenia and people at clinical risk
for psychosis (22), whereas three studies showed no difference
in schizophrenia (23–25). More recently, one study found no
evidence of higher DVR in high-risk individuals compared with
HCs (68). We chose not to include DVR in our analysis. The
interpretation of patient–control differences obtained by
dividing binding in a target region by that in a reference region
is complicated by the possibility that there are alterations in
specific binding in the reference region as well. In addition, the
reliability of DVR for TSPO radioligands has been found to be
low (69). Given the lack of a true reference region, VT is the
most suitable outcome for TSPO quantification under the
assumption that nondisplaceable binding does not differ be-
tween groups. Apart from glial cells, TSPO is also expressed in
perivascular and endothelial cells (55,70) and under certain
conditions also neurons (71). Further research is needed to
evaluate the contribution of these components to the obser-
vation of lower levels of VT in schizophrenia. Finally, while there
is as yet no published evidence showing an effect of the
fraction of free radiotracer in plasma on brain VT for TSPO
radioligands (72), it cannot be ruled out that potential patient–
control differences in free radiotracer might contribute to the
observed differences in VT. Of all the original studies included
in this meta-analysis that measured free radiotracer (22–24),
none found a significant difference between groups, suggest-
ing that this factor did not have a major influence on the
results.
In this IPD meta-analysis, the hierarchal statistical models
allowed us to investigate the difference in TSPO levels be-
tween patients with psychosis and HCs across five different
studies. The IPD approach offers many advantages over
traditional, aggregated meta-analysis (73). In this study
specifically, for example, it allowed us to examine the effect
of medication, investigate correlations between VT and
clinical measures, and control for potential cofounders such
as gender, all of which would not have been possible if effect
sizes had only been extracted from literature. By including
only studies employing second-generation radiotracers and
reporting the standard outcome measure VT, the analysisatry September 15, 2018; 84:433–442 www.sobp.org/journal 439
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Psychiatryfulfills the precondition of meta-analytical models that out-
comes should stem from the same underlying distribution of
effects. Synthesizing data in this way, we were able to
overcome the critical limitation of small sample sizes in the
individual reports. Despite this, the total number of included
subjects did not allow for investigations of specific sub-
groups such as different disease stages.
Conclusions
The current study shows that TSPO levels are lower across
several brain regions in patients with first-episode psychosis
and schizophrenia compared with HCs, suggesting an
altered function, or reduced density, of immune and glial
cells. Further work is needed to assess the exact biological
meaning of these changes using both clinical and trans-
lational studies.
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